Targeting different immune checkpoint pathways (PD-1/PD-L1, CTLA-4) can more effectively block the inhibitory signals used by cancer cells to evade the immune system, thereby enhancing T cell-mediated killing of tumor cells. The gene discussed is CD274; the disease is neoplasm.